HC Wainwright Maintains Buy Rating on Rhythm Pharmaceuticals, Sets $130 Target
HC Wainwright & Co. maintained its Buy rating on Rhythm Pharmaceuticals with a $130 price target. The target implies 43.2% upside from the Oct. 9 close of $90.78.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.